Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies

Nuclear Medicine and Biology

Volumn 33, Issue 7, 2006, Pages 831-840

  Gomes, Celia Maria Freitas ^a,b   van Paassen, Heidi ^a   Romeo, Salvatore ^a   Welling, Mick M ^a   Feitsma, R I J ^a   Abrunhosa, Antero J ^b   Botelho, M Filomena ^b   Hogendoorn, Pancras C W ^a   Pauwels, Ernest ^a   Cleton Jansen, Anne Marie ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

ABC transporters; Bone tumor; Cyclosporin A; Multidrug resistance; Sestamibi; Tetrofosmin

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CATION; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; IMATINIB; MESSENGER RNA; METHOTREXATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TETROFOSMIN TC 99M; TRACER;

ADULT; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMICAL PARAMETERS; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPOPHILICITY; MULTIDRUG RESISTANCE; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RNA ANALYSIS;

EID: 33749426881     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.07.011     Document Type: Article

References (51)

1. Rosen G., Caparros B., Huvos A.G., Kosloff C., Nirenberg A., Cacavio A., et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 (1982) 1221-1230
2. Meyers P.A., Gorlick R., Heller G., Casper E., Lane J., Huvos A.G., et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16 (1998) 2452-2458
3. Provisor A.J., Ettinger L.J., Nachman J.B., Krailo M.D., Makley J.T., Yunis E.J., et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15 (1997) 76-84
4. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10 (1992) 5-15
5. Hauben E.I., Weeden S., Pringle J., Van Marck E.A., and Hogendoorn P.C. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38 (2002) 1218-1225
6. Bacci G., Forni C., Ferrari S., Longhi A., Bertoni F., Mercuri M., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 25 (2003) 845-853
7. Smeland S., Muller C., Alvegard T.A., Wiklund T., Wiebe T., Bjork O., et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG: VIII. Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39 (2003) 488-494
8. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20 (2002) 776-790
9. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
10. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 53 (2002) 615-627
11. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
12. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
13. Kruh G.D., and Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 22 (2003) 7537-7552
14. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5 (2004) 21-53
15. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
16. Baldini N., Scotlandi K., Barbantibrodano G., Manara M.C., Maurici D., Bacci G., et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333 (1995) 1380-1385
17. Bodey B., Taylor C.R., Siegel S.E., and Kaiser H.E. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Anticancer Res 15 (1995) 2461-2468
18. Chan H.S., Grogan T.M., Haddad G., DeBoer G., and Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89 (1997) 1706-1715
19. Wunder J.S., Bull S.B., Aneliunas V., Lee P.D., Davis A.M., Beauchamp C.P., et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18 (2000) 2685-2694
20. Shnyder S.D., Hayes A.J., Pringle J., and Archer C.W. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 78 (1998) 757-759
21. Nooter K., Burger H., and Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymphoma 20 (1996) 381-387
22. Ota E., Abe Y., Ozeki Y., Iwasaki M., Inoue H., Yamazaki H., et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72 (1995) 550-554
23. Oda Y., Dockhorn-Dworniczak B., Jurgens H., and Roessner A. Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol 123 (1997) 237-239
24. Bruheim S., Bruland O.S., Breistol K., Maelandsmo G.M., and Fodstad O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 10 (2004) 133-141
25. Tsang W.P., Chau S.P., Fung K.P., Kong S.K., and Kwok T.T. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 51 (2003) 161-166
26. Burak Z., Moretti J., Ersoy O., Sanli U., Kantar M., Tamgac F., et al. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 44 (2003) 1394-1401
27. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91 (1999) 429-433
28. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59 (1999) 4559-4563
29. Fisher G.A., and Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9 (1995) 363-382
30. Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64 (2004) 2333-2337
31. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10 (2003) 159-165
32. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11 (2005) 2320-2326
33. Hendrikse N.H., Franssen E.J.F., van der Graaf W.T.A., Vaalburg W., and de Vries E.G.E. Visualization of multidrug resistance in vivo. Eur J Nucl Med 26 (1999) 283-293
34. Rozeman L.B., Hameetman L., Cleton-Jansen A.M., Taminiau A.H., Hogendoorn P.C., and Bovee J.V. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 205 (2005) 476-482
35. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (2002) [RESEARCH0034, electronic publication 2002 Jun 18]
36. Utsunomiya K., Ballinger J.R., Piquette-Miller M., Rauth A.M., Tang W., Su Z.-F., et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 27 (2000) 1786-1792
37. Pauwels E.K.J., McCready V.R., Stoot J.H.M.B., and van Deurzen D.F.P. The mechanism accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 25 (1998) 277-305
38. Ballinger J.R., Bannerman J., Boxen I., Firby P., Hartman N.G., and Moore M.J. Technetium-99m-Tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 37 (1996) 1578-1582
39. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., and Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53 (1993) 977-984
40. Chen W.S., Luker K.E., Dahlheimer J.L., Pica C.M., Luker G.D., and Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of Tc-99m-Tetrofosmin. Biochem Pharmacol 60 (2000) 413-426
41. Sun S.S., Hsieh J.F., Tsai S.C., Ho Y.J., and Kao C.H. Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res 20 (2000) 1467-1470
42. Del Vecchio S., Ciarmiello A., Pace L., Potena M.I., Carriero M.V., Mainolfi C., et al. Fractional retention of technetium-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38 (1997) 1348-1351
43. Arbab A.S., Koizumi K., Toyama K., and Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 37 (1996) 1551-1556
44. Platts E.A., North T.L., Pickett R.D., and Kelly J.D. Mechanism of uptake of technetium-tetrofosmin: I. Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 2 (1995) 317-326
45. Komiya S., Gebhardt M.C., Mangham D.C., and Inoue A. Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J Orthop Res 16 (1998) 15-22
46. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5 (1999) 621-627
47. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59 (1999) 2532-2535
48. Volk E.L., and Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63 (2003) 5538-5543
49. Serra M., Reverter-Branch G., Maurici D., Benini S., Shen J.N., Chano T., et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15 (2004) 151-160
50. Burak Z., Ersoy O., Moretti J.L., Erinc R., Ozcan Z., Dirlik A., et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 28 (2001) 1341-1350
51. Gorlick R., Liao A.C., Antonescu C., Huvos A.G., Healey J.H., Sowers R., et al. Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 7 (2001) 3065-3070